We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats.
Molecular and Cellular Endocrinology 2017 January 6
Many flavonoids are reported to be partial agonists of PPARγ and exert antidiabetic effects with fewer side effects compared with full agonists. Here, we assessed the effects of flavonoid dihydromyricetin (DHM) on glucose homeostasis in male Zucker diabetic fatty rats. Animals were treated with DHM (50-200 mg kg-1 ) or rosiglitazone (4 mg kg-1 ) once a day for 8 weeks. We found that DHM reduced fasting blood glucose and delayed the onset of hyperglycemia by 4 weeks. Furthermore, DHM preserved pancreatic β-cell mass, elevated adiponectin and improved lipid profile more vigorously than rosiglitazone. Notably, DHM decreased body weight gain and fat accumulation in both liver and adipose tissue, while rosiglitazone caused a significant increase of body weight and fat accumulation. DHM inhibited phosphorylation of PPARγ at serine 273 more efficiently than rosiglitazone. These results suggest that DHM exerts antidiabetic effects without causing excessive body weight gain via inhibition of PPARγ phosphorylation.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app